Sunday, October 1, 2023
Clinical Advances in
Vasodilatory shock results from multiple causes, of which sepsis is the most common. Nonseptic causes include severe acute pancreatitis, post cardiopulmonary bypass vasoplegia and other triggers for a systemic inflammatory response syndrome. Even brief hypotensive periods can result in myocardial and renal injury, and increased mortality in the critically ill. Further, refractory hypotension has a 30-day all-cause mortality greater than 50%. Our expert faculty shares strategies to optimize current therapies and promising evidence for new therapies for refractory vasodilatory shock.
Supported by an independent educational grant from
La Jolla Pharmaceutical Company
A quick guide on definitions, guidelines, and new strategies for the treatment of hypotension in patients with shock.
Download
Chawla LS, Chen S, Bellomo R, et al. Angiotensin converting enzyme defects in shock: implications for future therapy
Levy MM, Evans Le, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018;44:925-928.
Asfar P, Radermacher P, Ostermann M. MAP of 65: target of the past? Intensive Care Med. 2018;44:1551-1552.
Maheshwari K, Nathanson BH, Munson SH. The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients. Intensive Care Med. 2018.
Khanna A, English SW, Wang XS, et al; ATHOS-3 Investigators. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419-430.
Chair
Assistant Professor of Anesthesiology, Cleveland Clinic Lerner College of Medicine; Staff Intensivist, SICU and Center for Critical Care; Staff Anesthesiologist, Department of General Anesthesiology; Vice-Chief for Research Center for Critical Care, Staff Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio
Research Scientist, NovEx Novice to Expert Learning, St. Louis, Missouri
Professor of Internal Medicine, Pharmacology, Anesthesiology, and Emergency Medicine, School of Medicine, University of California, Davis, Sacramento, California
Professor of Medicine, Brown University; Chief, Division of Pulmonary, Critical Care, and Sleep Medicine; Medical Director, MICU Rhode Island Hospital, Providence, Rhode Island
Associate Professor, Pulmonary and Critical Care Medicine; Associate Professor, Emergency Medicine, University of Maryland School of Medicine; Director, Critical Care Medicine Fellowship; Co-Director, EM-IM/CCM Training Program; Co-Director, Critical Care Access and Flow, University of Maryland Medical Center, Baltimore, Maryland
Michael Cudahy Professor and Chair, Department of Outcomes Research, Cleveland Clinic, Cleveland, Ohio
Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: La Jolla Pharmaceutical Company; Medtronic, Inc.
Diabetes Chair
Has disclosed no relevant financial relationships.
Has disclosed the following relevant financial relationships
Served as a speaker or a member of a speakers bureau for: La Jolla Pharmaceuticals
Received grants for clinical research from: Bristol-Myers Squibb Company; La Jolla Pharmaceuticals
Has ddisclosed no relevant financial relationships.
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: La Jolla Pharmaceuticals
Owns stock, stock options, or bonds from: La Jolla Pharmaceuticals
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Edwards Lifesciences
Served as a speaker or a member of a speakers bureau for: Edwards Lifesciences
Received grants for clinical research from: Edwards Lifesciences